Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases — kidney, liver and lung fibrosis — the scar tissue goes rogue and strangles vital organs. These diseases are largely untreatable and ultimately fatal.
A new Northwestern Medicine study has newly identified a trigger of some fibrotic diseases and an experimental compound to treat it.
Fibrosis — a progressive scarring and hardening of internal organs — is estimated to cause 35 to 40 percent of deaths in the world. Fibrotic diseases include diabetic kidney fibrosis, alcoholic liver cirrhosis, hepatitis C, pulmonary fibrosis and nonalcoholic fatty liver disease, which may lead to fibrosis of the liver, the leading cause of liver transplant.
In one subset of human fibrosis cells, scientists discovered a delinquent gang of molecules that continually shouted at an immune receptor — the antennae on the cell — to produce scar tissue instead of quieting down and allowing the scar tissue to go back to sleep.
Scientists collaborated with a University of Colorado researcher who used crystallography and computer modeling to predict a molecule that could block the receptor that leads to the uncontrolled scarring. When they tested the molecule, T53, in three different mouse models of fibrosis, the abnormality was significantly reversed.
“Our study opens a new door into fibrosis by looking at it as an aberrant innate immune response and suggesting a novel approach to treat it,” said senior author Dr. John Varga, director of the Northwestern Scleroderma Program and the John and Nancy Hughes Distinguished Professor of Rheumatology at Northwestern University Feinberg School of Medicine.
The paper was published July 12 in the Journal of Clinical Investigation Insight.
“The leading cause of liver failure in western world is obesity and that’s because of liver fibrosis,” Varga said. “In the U.S., many of these diseases are lifestyle or age dependent. As we get fatter or older, they get worse.”
Most fibrotic disease likely begins as normal repair of an injury, scientists said. “But if the immune system produces too much of an initial scar, it can’t go back to normal,” Varga said. “You have an unhealed scar that keeps growing and can wipe out the entire organ.”
Not everyone’s fibrosis is caused by the same abnormality, Varga said. If the compound, T53, is eventually developed into an approved drug, it would be targeted to patients with the specific genetic signature identified in the study.
“There is an emerging direction for treating fibrosis with precision medicine,” said first author Swati Bhattacharyya, research associate professor of medicine in rheumatology and scientific director of the Scleroderma Research Laboratory at Feinberg. “Some people live with fibrotic disease for 30 years while others die in two years. We need to identify the rapid progressors from the slow progressors. That’s where precision medicine becomes really critical.”
“The results of this study are encouraging,” Varga said. “We are not saying this compound is ready to be a drug. It’s an initial compound that would need to be developed and tweaked. It would need significant funding to go to the next step.”
Learn more: Why internal scars won’t stop growing
The Latest on: Fibrosis
via Google News
The Latest on: Fibrosis
- Parents’ Suit Over Child Born With Cystic Fibrosis Revived on September 18, 2018 at 5:07 pm
Law360 (September 18, 2018, 7:53 PM EDT) -- A North Carolina appeals court has revived a suit over the birth of a child with cystic fibrosis following a doctor’s notification to the mother that she wa... […]
- Ofev Slows Idiopathic Pulmonary Fibrosis Progression Long-Term on September 18, 2018 at 1:50 pm
Treatment with Ofev (nintedanib; Boehringer Ingelheim) demonstrated long-term safety, efficacy, and tolerability in patients with idiopathic pulmonary fibrosis (IPF) with clinical efficacy lasting bey... […]
- Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis on September 18, 2018 at 7:39 am
We randomly assigned, in a 1:1 ratio, patients with IPF and a Dl CO of 35% or less of the predicted value to receive nintedanib at a dose of 150 mg twice daily plus sildenafil at a dose of 20 mg three ... […]
- HCV DAA Curative Therapy Associated With Liver Fibrosis Regression on September 18, 2018 at 6:26 am
Curing hepatitis C virus (HCV) infection with direct-acting antiretrovirals (DAAs) is associated with regression of liver fibrosis for most patients, according to results published in AIDS. The result... […]
- Speaking up about pulmonary fibrosis on September 16, 2018 at 8:28 am
ST. LOUIS - Sandra Uhlemeyer, the Lung Health Director for the American Lung Association, is at the studio Sunday morning and is speaking up about pulmonary fibrosis. Sandra talks about what this ... […]
- Raising money to fight cycstic fibrosis on September 16, 2018 at 7:10 am
BURLINGTON, Vt. A bench, squat and dead lift competition took place last weekend at Williston's Lift Vermont Gym to raise money for cystic fibrosis. The event was organized by 25-year-old Jarek Larive... […]
- Cystic Fibrosis - Pipeline Review, H2 2018 - ResearchAndMarkets.com on September 15, 2018 at 11:29 am
DUBLIN--(BUSINESS WIRE)--The "Cystic Fibrosis - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering. Cystic Fibrosis - Pipeline Review, H2 2018, provides ... […]
- Crossing for a Cure Raises $280,000 to Fight Cystic Fibrosis on September 11, 2018 at 5:13 pm
Saltwater is nature's medicine. It's good for your skin, your mental health and it helps fight inflammation. It also has incredible benefits for individuals battling cystic fibrosis. In 2011, Travis S... […]
- Breaking Down The NASH Fibrosis Market - Intercept, Genfit Primed For Potential Market Dominance on September 10, 2018 at 9:00 am
Intercept Pharmaceuticals and Genfit are leading the race to develop a drug for NASH fibrosis, and Allergan is just a few months behind. Intercept's obeticholic acid is already approved for PBC ... […]
via Bing News